Shares of PlasmaTech Biopharmaceuticals, Inc. (PTBI) are higher by nearly 9% to $10.34 in premarket trading on Wednesday after the company announced that the U.S. Food and Drug Administration had granted both Orphan Drug Designation and Rare Pediatric Disease Designation for both of PlasmaTech’s lead product candidates for the treatment of Sanfilippo Syndromes A and B.2.
“We are very pleased to announce that the FDA has provided these two important designations to our Sanfilippo drug candidates, reflecting their potential to address the significant unmet medical needs of children with these rare and devastating lysosomal storage diseases,” stated Tim Miller, Ph.D., President & CEO of PlasmaTech Biopharmaceuticals.
IsoRay, Inc. (ISR) shares rocketed 31.68% to $2.12 in premarket trading after the company reported that the survival rate at 5 years was 100% for Cesium-131 lung cancer treatment group, which included many high risk patients, and Cesium-131 added no noticeable side effects.
IsoRay CEO Dwight Babcock commented, “We are extremely excited to have our Cesium-131 isotope seeds and mesh used in the treatment of non-small cell lung cancers with such outstanding patient outcomes…With every success that has been reported, the medical community is rapidly becoming aware of the innovative alternative our Cesium-131 products offer to cancer patients.”
Shares of Genocea Biosciences, Inc. (GNCA) are up $2.65, or 24.88%, at $13.30 in premarket trading on Wednesday. The company today announced positive top-line data from its Phase 2 dose optimization trial of GEN-003.
“We are extremely pleased with these positive top-line results which have successfully allowed us to identify the optimal dose to advance into further trials,” said in a statement Chip Clark, president and chief executive officer of Genocea Biosciences.
Yahoo! Inc. (YHOO) shares climbed 2.95% to $42.19 in premarket trading following a statement from the company regarding IRS comments. Yahoo said it believes that the latest IRS statement on the matter is not specific to the planned Q4/15 spin-off of its remaining Alibaba Group Holdings (BABA) stake.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!